Among blue-chip constituents of the biotech index, Innovent Biologics (01801) dropped 3.3%, closing at HK$88.95; BeiGene (06160) fell 3%, closing at HK$208; CSPC Pharmaceutical Group (01093) declined 1.8%, closing at HK$8.9; non-blue-chip Zai Lab (09688) plunged 7.8%, closing at HK$17.5; and Yingji Biopharma-B (09606) dropped 4.5%, closing at HK$165.3.
Akeso (09926) plans to place 20 million new shares to no fewer than six independent investors, representing approximately 2.13% of its enlarged issued share capital, at a price of HK$97.76 per share, representing a 6.9% discount to the company's closing price of HK$105 the previous day, raising approximately HK$1.941 billion in net proceeds. Akeso fell 9.4%, closing at HK$95.15.
Currently, only two constituents of the biotech index rose against the market trend: Grand Pharma (00512) gained 1.3%, closing at HK$4.765; and GenScript Biotech-1000 (01548) rose 1.2%, closing at HK$36.
Currently, the Hang Seng Index stands at 24124, down 220 points or 0.9%, with main board turnover exceeding HK$13.2 billion. The Hang Seng China Enterprises Index is at 8096, down 78 points or 1%. The Hang Seng Tech Index is at 4106, down 30 points or 0.7%.
| Stock (Code) | Current Price (HK$) | Change (%) |
|---|---|---|
| Innovent Biologics (01801) | 88.95 | Down 3.26% |
| BeiGene (06160) | 208 | Down 2.99% |
| CSPC Pharmaceutical Group (01093) | 8.9 | Down 1.82% |
| Akeso (09926) | 95.15 | Down 9.38% |
| Zai Lab (09688) | 17.5 | Down 7.85% |
| Yingji Biopharma-B (09606) | 165.3 | Down 4.45% |
| Insilico Medicine (03696) | 41.96 | Down 3.81% |
| Grand Pharma (00512) | 4.765 | Up 1.28% |
